TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00972244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: once daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, 12 weeks
Study: NCT01649739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra
Description: There is 2 dosage:10mg Twice daily and 20mg Twice daily
Study: NCT04141787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)
Description: Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice.
Study: NCT00862966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: citrate
Description: comparison of different catheter lock solutions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: comparison of different lock solutions
Study: NCT02884817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: essential oils and ELA
Description: The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water
Description: The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
Study: NCT04111458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Tablet
Study: NCT00953628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10000 IU urinary HCG
Description: bolus 10000 units for ovulation triggering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mcg recombinant HCG
Description: bolus 250 mcg for ovulation triggering in IVF patients
Study: NCT02610439

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03667820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80mg tablet to be taken once daily.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: Stereotactic Ablative Radiation (SABR)
Study: NCT04493476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese herbal formula
Description: Chinese herbal formula

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese herbal formula
Description: Chinese herbal formula
Study: NCT00194792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin pamoate
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo lumpectomy or mastectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00255151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Study: NCT02820740

Intervention type: DEVICE
Group type: OTHER
Intervention: NeuroBlate System
Description: Laser Interstitial Thermal Therapy
Study: NCT03547635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AMNIOEXCEL Plus Amniotic Membrane
Description: AMNIOEXCEL Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering. This product is an allograft tissue intended for homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AMNIOEXCEL Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271. All donor recoveries are performed by BioDlogics, LLC, and adhere to the regulations regarding HCT/P recovery and the screening and testing of the tissue donor as verified through supplier audits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A Marketed Comparator
Description: bi-layered skin substitute: the epidermal layer is formed by human keratinocytes and has a well-differentiated stratum corneum; the dermal layer is composed of human fibroblasts in a bovine Type I collagen lattice. It is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1-month duration and which have not adequately responded to conventional ulcer therapy. This product is also indicated for use with standard DFU care for the treatment of full-thickness neuropathic DFUs of greater than three weeks' duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule or bone exposure.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: * Coban™~* Conforming gauze~* Optifoam® non-adhesive dressing~* Cotton Gauze~* Normal saline (liquid or gel)~* Non-adhering dressings~* Steristrips~* An offloading boot (Pneumatic Short Leg Walker), as appropriate
Study: NCT02073006

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural Fibre Supplement
Description: Natural Fibre Supplement 2 doses per day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Natural Fibre Supplement
Description: Natural Fibre Supplement 2 doses per day for 4 weeks
Study: NCT02697539

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AmF/SnF2
Description: AmF/SnF2 dentifrice used twice daily for 2 minutes for 12 weeks
Study: NCT02947568

Intervention type: OTHER
Intervention: non-interventional study

Intervention type: OTHER
Intervention: non-interventional study

Intervention type: OTHER
Intervention: non-interventional study
Study: NCT05416671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guided narrative technique-writing
Description: The experimental group underwent the psychological intervention of guided narrative technique-writing with the theme of teacher criticism for 20 to 30 minutes once a day for three consecutive days.
Study: NCT03276936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX103 1.5%
Description: FMX103 1.5% minocycline foam
Study: NCT03533036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: applied VR headset
Description: Virtual reality (VR) is a three-dimensional experience created by a headset fitted with a video display. The device, designed to be worn on the face, immerses the viewer in a virtual world and can create a visual distraction from the patient's present situation. We will use a commercially available VR device, comprised of a phone and headset. The phone is inserted into the headset to act as the visual display that can create three dimensional environments. The patient will then choose the virtual reality experience she prefers from the two relaxation programs available. The VR device will be introduced to the participant and fitted to her head prior to the procedure. The device is intended to be worn during the full length of the procedure until the conclusion of the D\&C, however the participant may decide to stop wearing the device and choose to end the VR experience at any time.
Study: NCT02850887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general endotracheal anesthesia
Description: sedation with the use of endotracheal intubation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: deep sedation without endotracheal intubation
Description: deep sedation without endotracheal airway management.
Study: NCT01345123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of condition specific shared decision making (SDM) aids only
Description: Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of condition specific shared decision making (SDM) aids only
Description: Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic outreach and support by Health Coach
Description: Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
Study: NCT00657631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, \& Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl \& Wilson, 1999).
Study: NCT01661361

Intervention type: PROCEDURE
Intervention: blood levels
Study: NCT01763905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Subcutaneous injection
Study: NCT00920686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXN-188
Description: NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
Study: NCT00920686

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administered as 3 placebo hard gelatin capsules
Study: NCT01763905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Tablet for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ezetimibe
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ezetimibe
Description: Tablet for oral administration
Study: NCT03219749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Eligible participants will undergo 6 weeks of a combined aerobic and resistance exercise intervention. Training will take place 3 times per week for 1 hour. Forty minutes will be dedicated to aerobic training while 15 to 20 minutes will be devoted to resistance training.
Study: NCT00137852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
Study: NCT00920686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan succinate
Description: administered in a hard gelatin capsule with 2 capsules of placebo
Study: NCT03899818

Intervention type: DEVICE
Group type: OTHER
Intervention: drug-eluting balloon
Description: Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)

Intervention type: DEVICE
Group type: OTHER
Intervention: drug-eluting stent
Description: Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).
Study: NCT04012853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Treatment group will receive 20 minutes of tDCS stimulation at 2.0 mA administered daily for five days per week and a total of 4 weeks. During the 20minute treatment session, both treatment and sham groups will complete mindfulness meditation via VA health system approved program (Mindfulness Coach).
Study: NCT04008836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-PLUS Meter
Description: Blood Glucose Monitoring System (BGMS)
Study: NCT01230619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568
Description: RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
Study: NCT02327104

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based Relapse Prevention
Description: The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention
Description: The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.

Intervention type: OTHER
Group type: OTHER
Intervention: Brazilian Ministry of Health Protocol
Description: The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
Study: NCT01559480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desogestrel
Description: Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule takes 1 capsule before bedtime for 6 months
Study: NCT03504644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT02697539

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mHA
Description: microcrystalline zinc-hydroxyapatite (mHA) dentifrice dentifrice used twice daily for 2 minutes for 12 weeks.
Study: NCT00932594

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjust the TMJ Pressure to Normal Value
Description: Adjust the TMJ Pressure by the Operation Only Once for Each Patient
Study: NCT01319565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Arm 1 and Arm 2 - Days 1 to 4: Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) for up to 5 days (maximum 15 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Arm 1 and Arm 2 - Days 1 to 4: Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) for up to 5 days (maximum 15 doses).
Study: NCT03504644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Liposomal
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Liposomal
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01192542

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A prototype lens
Description: Prototype silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A prototype lens
Description: Prototype silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: enfilcon A lens
Description: Marketed silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: enfilcon A lens
Description: Marketed silicone hydrogel contact lens
Study: NCT01228448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: In-Room PET scan
Study: NCT00802490

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain-Computer Interface System
Description: Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Brain-Computer Interface System
Description: Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
Study: NCT04533464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem
Description: Intravenous Infusion
Study: NCT00932594

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjust the TMJ Pressure to Normal Value
Description: Adjust the TMJ Pressure by the Operation Only Once for Each Patient

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjust the TMJ Pressure to Normal Value
Description: Adjust the TMJ Pressure by the Operation Only Once for Each Patient

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjust the TMJ Pressure to Normal Value
Description: Adjust the TMJ Pressure by the Operation Only Once for Each Patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Do not adjust the pressure of TMJ
Description: Do the treatments normally without additional treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Do not adjust the pressure of TMJ
Description: Do the treatments normally without additional treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Do not adjust the pressure of TMJ
Description: Do the treatments normally without additional treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Do not adjust the pressure of TMJ
Description: Do the treatments normally without additional treatment
Study: NCT04533464

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Infusion
Study: NCT03236064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycols
Description: Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
Study: NCT02797249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
Study: NCT01319565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Arm 1 and Arm 2 - Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mL D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.